RBC Europe’s TherapeuticsMD TXMD Stock Holding History

RBC Europe’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-200	Closed	-$48.7K	–	1180
2018 Q1	$48.7K	Hold	200	–	–	0.01%	464
2017 Q4	$60.4K	Hold	200	–	–	0.01%	434
2017 Q3	$52.9K	Buy	+200	New	+$57.8K	0.01%	459

Other funds holding TXMD

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

RBC Europe's TXMD Position: Q2 2018 in Review

RBC Europe sold out of TherapeuticsMD (TXMD) in Q2 2018, closing a stake of 200 shares — an estimated $48.7K sold.

RBC Europe first reported a position in TXMD in Q3 2017 and held it in 3 quarters. The position peaked at $60.4K in Q4 2017. 144 funds tracked by Wall St. Rank hold TXMD as of Q2 2018.

RBC Europe reported no remaining TherapeuticsMD position as of Q2 2018 after selling out during the quarter.
RBC Europe sold 200 TherapeuticsMD shares in Q2 2018, an estimated $48.7K.
RBC Europe first reported a position in TherapeuticsMD in Q3 2017 and held it in 3 quarters.
RBC Europe's TherapeuticsMD position peaked at $60.4K in Q4 2017.
144 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2018.

Based on RBC Europe's 13F filing for Q2 2018, filed 9 Nov 2023.